Mikaela Naylon Give Kids a Chance Act

Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program

Client expense: $880,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: Not reported · Firm income: $90,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.

Client expense: $440,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.

Client expense: Not reported · Firm income: $50,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications OMB Uniform Guidance Oversight H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act

Client expense: Not reported · Firm income: $70,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the Bolstering Research And Innovation Now (BRAIN) Act (H.R.2767/S.1330), Mikaela Naylon Give Kids a Chance Act (H.R.1262)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements, including purchasing through HSA funds. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. H.R. 1262, Give Kids a Chance Act of 2025. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 932, Give Kids a Chance Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026.

Client expense: $2,040,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Give kids a chance act H.R.1262; issues related to rare pediatric disease and priority review vouchers

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1262/S. 932 - Mikaela Naylon Give Kids a Chance Act General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025FDA Rare Disease Innovation Hub Fiscal Year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R. 4121 / S. 2256) H.R.6280/S.3607 - Access to Genetic Counselor Services Act of 2025/Access to Genetic Counselor Services Act of 2026 H.R.4709 - Newborn Screening Saves Lives Reauthorization Act of 2025 General discussions about genetic testing, diagnostics General discussions about accelerated approval pathway (AAP)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues regarding childrens health care coverage and access to care under Medicaid, CHIP, the Exchanges, TRICARE, and private insurance Issues regarding childrens mental health and the national emergency in childrens mental health, including mental health parity, the mental health workforce, suicide and injury prevention, and related access issues. Issue regarding Medicaid supplemental payments and directed payments. Issues regarding the importance of Medicaid to children, including military and veteran families.  Issues regarding Medicaid support for providers caring for children on Medicaid, including DSH payments. Issues regarding Children's Hospitals Graduate Medical Education (CHGME) program and funding. Issues related to 340B Drug Pricing Program, the Prescription Drug User Fee Act, prescription drug pricing, drug shortages, drug compounding, high-cost drugs/therapies and pharmaceutical supply chain. Issues related to pediatric workforce, Medicare GME and the Pediatric Specialty Loan Repayment Program. Issues related to hospital financing. Issues regarding site neutrality, facility fees, and price transparency in health care.  Issues regarding pediatric pandemic and disaster preparedness and response and emergency preparedness, including work with the Pediatric Pandemic Network (PPN) and related to the Pandemic and All-Hazards Preparedness Act (PAHPA). Issues related to Emergency Medical Services for Children (EMSC). Issues related to mental health services in schools Issues regarding Artificial Intelligence (AI). Issues regarding oversight and implementation of EPSDT. Issues involving pediatric medical research and funding, specifically including research at the National Institutes of Health. Issues involving gun violence prevention. Issues regarding health care innovation. Issues involving Making America Healthy Again. Issues involving Medical Device User Fee Authorization. Issues involving biomedical research policies. Issues involving the 988 Suicide Prevention Lifeline. Issues involving the Community Mental Health Services Block Grant. Issues involving the Pediatric Mental Health Care Access Program. Issues involving telehealth. Issues involving Appropriations for pediatric health care programs. Issues involving Hospital at Home. Issues involving the Lorna Breen Health Care Provider Protections program. Issues involving National Provider Identifier. H.R. 5582/S.2355 Patients Deserve Price Tags Act H.R. 6396 Kid Providing Resources for Optimal Outcomes Against Fatalities (Kid PROOF) Act H.R.169/S.357 Prevent Family Fire Act H.R.4768/S.2448 Health Care Fairness for Military Families Act of 2025 H.R. 1509/S. 752 Accelerating Kids Access to Care Act H.R. 1735 / S. 779, The Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 2587/S. 1266, Youth Mental Health Research Act H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act H.R.3255/S.1673, Mental Health Infrastructure Act Issues related Pub. L No. 119-21; specifically state direct payments. H.R. 3890, Resident Physician Shortage Reduction Act of 2025 H.R. 1262/S.932, Give Kids a Chance Act H.R. 3505, Barriers to Suicide Act H.R. 4262, To reauthorize programs related to health professions education, and for other purposes.

Client expense: $1,370,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

Issues regarding childrens health care coverage and access to care under Medicaid and CHIP, including oversight and implementation of Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) and guidance to states.   Issues related to implementation of aspects of childrens health coverage under Medicaid and CHIP. Issues regarding mental health parity and the mental health workforce. Issue regarding Medicaid supplemental payments, including Disproportionate Share Hospitals (DSH) and directed payments. Issues regarding out of state care for children enrolled in Medicaid. Issues related to Hospital at Home. H.R. 1262/S.932 Give Kids a Chance Act H.R. 1509/S. 752 Accelerating Kids Access to Care Act Issues related Pub. L No. 119-21; specifically state directed payments.

Client expense: $1,370,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act

Client expense: $36,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.

Client expense: $36,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: Not reported · Firm income: $90,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Mental Health issues (incl. mental health parity, suicide prevention) General Health Care issues for people living with Tourette Syndrome or other Tic Disorders (preexisting coverage, Medicare/Medicaid) Medicare Part D Protected Class Drugs Coverage, Part D coverage Research, medical and scientific issues (including BRAIN initiative) Drug Pricing Broadly Telehealth (including HR 4206/ S 1261 - Connect for Health Act of 2025) H.R. 3514/S.1816- Improving Seniors Timely Access to Care Act of 2025 H.R. 5509/S. 2903- Safe Step Act of 2025 H.R. 1262/S. 932- Give Kids a Chance Act

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program H.R.9504: Tax Exempt Hospital Transparency Act 340B Program Implementation & Oversight H.R. 9599 - SECURE 340B Act Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation (MFN) policy Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Utilization management policies Clinical trial data in China S.3788: CLEAR Labels Act S. 4784/H.R. 8800: National Defense Authorization Act for Fiscal Year 2027

Client expense: $1,410,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.

Client expense: $700,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.1262/S.932, Give Kids a Chance Act H.R.1509/S.752, Accelerating Kids Access to Care Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act

Client expense: Not reported · Firm income: $70,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- 45Q Repeal Act of 2025H.R. 1946 House - Carbon Capture Utilization Parity ActS.542/H.R. 1262 Senate/House - Critical Mineral Independence Act of 2025No Bill # Senate - Critical Minerals Security Act of 2025No Bill # Senate/House - Energy Permitting Reform Act of 2025No Bill # Senate - IMPACT ActH.R. 1534 House - Inflation Reduction ActNo Bill # House/Senate/DOE/DOL - Infrastructure Investment and Jobs ActNo Bill # House/Senate/DOE/DOL - Intergovernmental Critical Minerals Task Force ActNo Bill # Senate - Methane Reduction and Economic Growth ActH.R. 1881 House - Permitting for Mining Needs Act No Bill # House - Securing American Critical Minerals Act No Bill # House - Securing Americas Critical Minerals Supply ActNo Bill # House - Supply Chain Security and Resilience ActNo Bill # House - UMWA Energy Transition Initiative No Bill# Senate/House

Client expense: $80,000 · Firm income: Not reported

Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act HR 5509, Safe Step Act, Provisions related step therapy protocols H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7391, the Community Health Center Drug Pricing Protection Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First S. 891, Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S.4784, An original bill to authorize appropriations for fiscal year 2027 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes, Provisions related to the pharmaceutical industry. Smucker's VICP bill Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Vaccine policy issues

Client expense: $890,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Give Kids a Chance Act (H.R.1262),(S.932) and other issues related to therapeutics

Client expense: Not reported · Firm income: $60,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the Bolstering Research And Innovation Now (BRAIN) Act (H.R.2767/S.1330), Mikaela Naylon Give Kids a Chance Act (H.R.1262)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.

Client expense: Not reported · Firm income: $50,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues regarding childrens health care coverage and access to care under Medicaid and CHIP, including oversight and implementation of Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) and guidance to states.   Issues related to implementation of aspects of childrens health coverage under Medicaid and CHIP. Issues regarding mental health parity and the mental health workforce. Issue regarding Medicaid supplemental payments, including Disproportionate Share Hospitals (DSH) and directed payments. Issues regarding out of state care for children enrolled in Medicaid. Issues related to Hospital at Home. Issues related to Make America Healthy Again. H.R. 1262/S.932 Give Kids a Chance Act H.R. 1509/S. 752 Accelerating Kids Access to Care Act Issues related Pub. L No. 119-21

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues regarding childrens health care coverage and access to care under Medicaid, CHIP, the Exchanges, TRICARE, and private insurance Issues regarding childrens mental health and the national emergency in childrens mental health, including mental health parity, the mental health workforce, suicide and injury prevention, and related access issues. Issue regarding Medicaid supplemental payments and directed payments. Issues regarding the importance of Medicaid to children, including military and veteran families.  Issues regarding Medicaid support for providers caring for children on Medicaid, including DSH payments. Issues regarding Children's Hospitals Graduate Medical Education (CHGME) program and funding. Issues related to 340B Drug Pricing Program, the Prescription Drug User Fee Act, prescription drug pricing, drug shortages, drug compounding, high-cost drugs/therapies and pharmaceutical supply chain. Issues related to pediatric workforce, Medicare GME and the Pediatric Specialty Loan Repayment Program. Issues related to hospital financing. Issues regarding site neutrality, facility fees, and price transparency in health care.  Issues regarding pediatric pandemic and disaster preparedness and response and emergency preparedness, including work with the Pediatric Pandemic Network (PPN) and related to the Pandemic and All-Hazards Preparedness Act (PAHPA). Issues related to Emergency Medical Services for Children (EMSC). Issues related to mental health services in schools Issues regarding Artificial Intelligence (AI). Issues regarding oversight and implementation of EPSDT. Issues involving pediatric medical research and funding, specifically including research at the National Institutes of Health. Issues involving gun violence prevention. Issues regarding health care innovation. Issues involving Making America Healthy Again. Issues involving Medical Device User Fee Authorization. Issues involving biomedical research policies. Issues involving the 988 Suicide Prevention Lifeline. Issues involving the Community Mental Health Services Block Grant. Issues involving the Pediatric Mental Health Care Access Program. Issues involving telehealth. Issues involving Appropriations for pediatric health care programs. H.R.169/S.357 Prevent Family Fire Act H.R.4768/S.2448 Health Care Fairness for Military Families Act of 2025 H.R. 1509/S. 752 Accelerating Kids Access to Care Act H.R. 1735 / S. 779, The Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 2587/S. 1266, Youth Mental Health Research Act H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act H.R.3255/S.1673, Mental Health Infrastructure Act Issues related Pub. L No. 119-21 H.R. 3890, Resident Physician Shortage Reduction Act of 2025 H.R. 1262/S.932, Give Kids a Chance Act H.R. 3505, Barriers to Suicide Act H.R. 4262, To reauthorize programs related to health professions education, and for other purposes.

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office

Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1262/S. 932, Give Kids A Chance Act of 2025 H.R. 955, HOPE Act of 2025 H.R. 1, One Big Beautiful Bill Act - healthcare provisions

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Give kids a chance act H.R.1262; issues related to rare pediatric disease and priority review vouchers

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Issues regarding childrens health care coverage and access to care under Medicaid, CHIP, the Exchanges, TRICARE, and private insurance Issues regarding childrens mental health and the national emergency in childrens mental health, including mental health parity, the mental health workforce, suicide and injury prevention, and related access issues. Issue regarding Medicaid supplemental payments and directed payments. Issues regarding the importance of Medicaid to children, including military and veteran families.  Issues regarding Medicaid support for providers caring for children on Medicaid, including DSH payments. Issues regarding Children's Hospitals Graduate Medical Education (CHGME) program and funding. Issues related to 340B Drug Pricing Program, the Prescription Drug User Fee Act, prescription drug pricing, drug shortages, drug compounding, high-cost drugs/therapies and pharmaceutical supply chain. Issues related to pediatric workforce, Medicare GME and the Pediatric Specialty Loan Repayment Program. Issues related to hospital financing. Issues regarding site neutrality, facility fees, and price transparency in health care.  Issues regarding pediatric pandemic and disaster preparedness and response and emergency preparedness, including work with the Pediatric Pandemic Network (PPN) and related to the Pandemic and All-Hazards Preparedness Act (PAHPA). Issues related to Emergency Medical Services for Children (EMSC). Issues related to mental health services in schools Issues regarding Artificial Intelligence (AI). Issues regarding oversight and implementation of EPSDT. Issues involving pediatric medical research and funding, specifically including research at the National Institutes of Health. Issues involving gun violence prevention. Issues regarding health care innovation. Issues involving Making America Healthy Again. Issues involving Medical Device User Fee Authorization. Issues involving biomedical research policies. Issues involving the 988 Suicide Prevention Lifeline. Issues involving the Community Mental Health Services Block Grant. Issues involving the Pediatric Mental Health Care Access Program. Issues involving telehealth. Issues involving Appropriations for pediatric health care programs. H.R.169/S.357 Prevent Family Fire Act H.R.4768/S.2448 Health Care Fairness for Military Families Act of 2025 H.R. 1509/S. 752 Accelerating Kids Access to Care Act H.R. 1735 / S. 779, The Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 2587/S. 1266, Youth Mental Health Research Act H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act H.R.3255/S.1673, Mental Health Infrastructure Act Issues related Pub. L No. 119-21 H.R. 3890, Resident Physician Shortage Reduction Act of 2025 H.R. 1262/S.932, Give Kids a Chance Act H.R. 3505, Barriers to Suicide Act H.R. 4262, To reauthorize programs related to health professions education, and for other purposes.

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office

Issues regarding childrens health care coverage and access to care under Medicaid and CHIP, including oversight and implementation of Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) and guidance to states.   Issues related to implementation of aspects of childrens health coverage under Medicaid and CHIP. Issues regarding mental health parity and the mental health workforce. Issue regarding Medicaid supplemental payments, including Disproportionate Share Hospitals (DSH) and directed payments. Issues regarding out of state care for children enrolled in Medicaid. Issues related to Hospital at Home. Issues related to Make America Healthy Again. H.R. 1262/S.932 Give Kids a Chance Act H.R. 1509/S. 752 Accelerating Kids Access to Care Act Issues related Pub. L No. 119-21

Client expense: $1,440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE